Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure

References

• Augusti A, Beasley R, Celli BR, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnoses, management, and prevention of COPD. 2020. Available from: http://www.goldcopd.org. Accessed May 27, 2021.
   Google Scholar
• Jones PW. Issues concerning health-related quality of life in COPD. Chest. 1995;107(5 Suppl):187S–193S. doi:10.1378/chest.107.5_Supplement.187S
   PubMed Web of Science ®Google Scholar
• Duiverman ML, Wempe JB, Bladder G, Kerstjens HAM, Wijkstra PJ. Health-related quality of life in COPD patients with chronic respiratory failure. Eur Respir J. 2008;32(2):379–386. doi:10.1183/09031936.00163607
   PubMed Web of Science ®Google Scholar
• Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3(56):1–8. doi:10.1186/1477-7525-3-56
   Google Scholar
• Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018;3(e4):2018–2020.
   Google Scholar
• Bilde L, Rud Svenning A, Dollerup J, Bække Borgeskov H, Lange P. The cost of treating patients with COPD in Denmark - a population study of COPD patients compared with non-COPD controls. Respir Med. 2007;101(3):539–546. doi:10.1016/j.rmed.2006.06.020
   Web of Science ®Google Scholar
• Flachs EM, Eriksen LKM, Ryd JT, Dibba E, Skov-Ettrup LJK. Sygdomsbyrden I Danmark - Sygdomme [The Disease Burden in Denmark - Diseases]. Sundhedsstyrelsen. 2015.
   Google Scholar
• Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5(5):212–227. doi:10.1177/2040622314532862
   PubMedGoogle Scholar
• Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. J Chron Obstruct Pulmon Dis. 2010;7(3):214–228. doi:10.3109/15412555.2010.481697
   Web of Science ®Google Scholar
• Geitona M, Hatzikou M, Steiropoulos P, Alexopoulos EC, Bouros D. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med. 2011;105(3):402–409. doi:10.1016/j.rmed.2010.09.020
   PubMed Web of Science ®Google Scholar
• Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. J Chron Obstruct Pulmon Dis. 2012;9(2):131–141. doi:10.3109/15412555.2011.650239
   Web of Science ®Google Scholar
• Press VG, Konetzka RT, White SR. Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program. Curr Opin Pulm Med. 2018;24(2):138–146. doi:10.1097/MCP.0000000000000454
   PubMed Web of Science ®Google Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J COPD. 2014;9:65–73. doi:10.2147/COPD.S54417
   Google Scholar
• Faes K, De Frène V, Cohen J, Annemans L. Resource use and health care costs of COPD patients at the end of life: a systematic review. J Pain Symptom Manage. 2016;52(4):588–599. doi:10.1016/j.jpainsymman.2016.04.007
   PubMed Web of Science ®Google Scholar
• García-Polo C, Alcázar-Navarrete B, Ruiz-Iturriaga LA, et al. Factors associated with high healthcare resource utilisation among COPD patients. Respir Med. 2012;106(12):1734–1742. doi:10.1016/j.rmed.2012.09.009
   PubMed Web of Science ®Google Scholar
• Persson HL, Lyth J, Wiréhn AB, Lind L. Elderly patients with COPD require more health care than elderly heart failure patients do in a hospital-based home care setting. Int J COPD. 2019;14:1569–1581. doi:10.2147/COPD.S207621
   Google Scholar
• FitzGerald JM, Haddon JM, Bradley-Kennedy C, et al. Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J. 2007;14(3):145–152. doi:10.1155/2007/921914
   PubMed Web of Science ®Google Scholar
• Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336–349. doi:10.1111/ijcp.12522
   PubMed Web of Science ®Google Scholar
• Storgaard LH, Hockey H, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched nasal high flow treatment in COPD with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195–1205. doi:10.2147/COPD.S159666
   PubMed Web of Science ®Google Scholar
• Elshof J, Duiverman ML. Clinical evidence of nasal high-flow therapy in chronic obstructive pulmonary disease patients. Respiration. 2020;99(2):140–153. doi:10.1159/000505583
   PubMed Web of Science ®Google Scholar
• Nagata K, Kikuchi T, Horie T, et al. Domiciliary high-flow nasal cannula oxygen therapy for patients with stable hypercapnic chronic obstructive pulmonary disease a multicenter randomized crossover trial. Ann Am Thorac Soc. 2018;15(4):432–439. doi:10.1513/AnnalsATS.201706-425OC
   Web of Science ®Google Scholar
• Rea H, McAuley S, Jayaram L, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med. 2010;104(4):525–533. doi:10.1016/j.rmed.2009.12.016
   PubMed Web of Science ®Google Scholar
• Storgaard LH, Hockey HU, Weinreich UM. Development in PaCO2 over 12 months in patients with COPD with persistent hypercapnic respiratory failure treated with high-flow nasal cannula - post-hoc analysis from a randomised controlled trial. BMJ Open Respir Res. 2020;7:1. doi:10.1136/bmjresp-2020-000712
   Web of Science ®Google Scholar
• Milne RJ, Hockey H, Rea H. Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis. Value Health. 2014;17(4):320–327. doi:10.1016/j.jval.2014.01.007
   PubMed Web of Science ®Google Scholar
• Hardinge M, Annandale J, Bourne S, et al. British Thoracic Society guidelines for home oxygen use in adults: accredited by NICE. Thorax. 2015;70(suppl 1):i1–i43. doi:10.1136/thoraxjnl-2015-206865
   PubMed Web of Science ®Google Scholar
• Drummond MF, Schulpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015.
   Google Scholar
• Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR good research practices task force report. Value Health. 2015;18(2):161–172. doi:10.1016/j.jval.2015.02.001
   PubMed Web of Science ®Google Scholar
• Valutakurser [Exchange rates]. Valutakurser. 2019. Available from: https://valutakurser.dk/. Accessed August 15, 2020.
   Google Scholar
• Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85:25–31. doi:10.1016/S0954-6111(06)80166-6
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
   PubMed Web of Science ®Google Scholar
• Honorartabel [Fee table]. Lægeforeningen. 2018. Available from: https://www.laeger.dk/sites/default/files/overenskomst_om_almen_praksis_ok18_endelig_udgave.pdf. Accessed May 31, 2020.
   Google Scholar
• Afregning og finansiering (DRG) [Reimbursement and financing (DRG)]. Sundhedsdatastyrelsen. Available from: https://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering. Accessed June 28, 2020.
   Google Scholar
• Priser på medicin [Prices on medicines]. Lægemiddelstyrelsen. 2020. Available from: https://laegemiddelstyrelsen.dk/da/tilskud/priser/#. Accessed May 31, 2020.
   Google Scholar
• Statistikbanken - LONS20: løn efter arbejdsfunktion, sektor, aflønningsform, lønmodtagergruppe, lønkomponenter og køn [Statistikbanken - LONS20: wages estimated based on job function, sector, payment form, employment group, wage component and gender]. Danmarks Statistik. 2019. Available from: www.statistikbanken.dk. Accessed June 6, 2020.
   Google Scholar
• Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157–1170. doi:10.1007/s40273-014-0193-3
   PubMed Web of Science ®Google Scholar
• Gray A, Wordsworth S, Wolstenholme JL, Clarke PM. Applied Methods of Cost-Effectiveness Analysis in Healthcare. Oxford University Press; 2010.
   Google Scholar
• Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14:487–496. doi:10.1002/hec.944
   PubMed Web of Science ®Google Scholar
• van Asselt AD, van Mastrigt GA, Dirksen CD, Arntz A, Severens JL, Kessels AGH. How to deal with cost differences at baseline. Pharmacoeconomics. 2009;27(6):519–528. doi:10.2165/00019053-200927060-00007
   Web of Science ®Google Scholar
• Sabrina Storgaard Sørensen. Additional analyses of cost-effectiveness of domiciliary high flow nasal cannula treatment in COPD patients with chronic respiratory failure. 2021. Available from: https://vbn.aau.dk/ws/portalfiles/portal/410910107/Additional_analyses_of_Cost_effectiveness_of_Domiciliary_High_Flow_Nasal_Cannula_treatment_in_COPD_patients.pdf. Accessed May 27, 2021.
   Google Scholar
• Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. Int J COPD. 2018;13:2301–2311. doi:10.2147/COPD.S163795
   Google Scholar
• Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.0152618
   PubMed Web of Science ®Google Scholar
• O’Connor S. Tele-health-monitoring may decrease emergency room visits and hospitalisation in patients with COPD. Evid Based Nurs. 2020;23:18. doi:10.1136/ebnurs-2019-103080
   Google Scholar
• Sorenson C, Tarricone R, Siebert M, Drummond M. Applying health economics for policy decision making: do devices differ from drugs? Europace. 2011;13:ii54–ii58. doi:10.1093/europace/eur089
   PubMed Web of Science ®Google Scholar
• Dretzke J, Blissett D, Dave C, et al. The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2015;19(81):1–246.
   Web of Science ®Google Scholar
• Nicolini A, Stieglitz S, Bou-khalil P, Esquinas A. Cost-utility of non-invasive mechanical ventilation: analysis and implications in acute respiratory failure. A brief narrative review. Respir Investig. 2018;56(3):207–213. doi:10.1016/j.resinv.2017.12.011
   Web of Science ®Google Scholar
• Bräunlich J, Mauersberger F, Wirtz H. Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent. BMC Pulm Med. 2018;18(14). doi:10.1186/s12890-018-0576-x
   Web of Science ®Google Scholar
• Braunlich J, Seyfarth H-J, Wirtz H. Nasal high-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report. Multidiscip Respir Med. 2015;10(27):1–3. doi:10.4081/mrm.2015.299
   Google Scholar
• Pisani L, Betti S, Biglia C, et al. Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a prospective pilot study. BMC Pulm Med. 2020;20(12):1–9. doi:10.1186/s12890-020-1048-7
   Web of Science ®Google Scholar
• Crimi C, Noto A, Princi P, et al. Domiciliary non-invasive ventilation in COPD: an international survey of indications and practices. J Chron Obstruct Pulmon Dis. 2016;13(4):483–490. doi:10.3109/15412555.2015.1108960
   PubMed Web of Science ®Google Scholar
• Xie F, Gaebel K, Perampaladas K, Doble B, Pullenayegum E. Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist. Med Decis Mak. 2014;34(1):8–20. doi:10.1177/0272989X13480852
   PubMed Web of Science ®Google Scholar
• Gerlinger C, Bamber L, Leverkus F, et al. Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results. BMC Res Notes. 2019;12(18). doi:10.1186/s13104-019-4067-9
   Web of Science ®Google Scholar
• Wittrup-Jensen K, Lauridsen J, Pedersen K. Modelling Danish EuroQol (EQ-5D) tariffs by applying the time trade-off method. Health Econ Pap Ser. 2008. Available from: http://static.sdu.dk/mediafiles/Files/Om_SDU/Centre/c_ist_sundoke/Forskningsdokumenter/publications/Workingpapers/20084.pdf. Accessed May 27, 2021.
   Google Scholar